国家农业综合开发办公室关于印发《国家农业综合开发县管理暂行办法》的通知

作者:法律资料网 时间:2024-05-30 21:30:05   浏览:9460   来源:法律资料网
下载地址: 点击此处下载

国家农业综合开发办公室关于印发《国家农业综合开发县管理暂行办法》的通知

国家农业综合开发办公室


国家农业综合开发办公室关于印发《国家农业综合开发县管理暂行办法》的通知

2004年3月12日 国农办[2004]26号

各省、自治区、直辖市、计划单列市财政厅(局)、农业综合开发办公室(局),新疆生产建设兵团财务局、农业综合开发办公室,农业部农业综合开发办公室:
  为了加强国家农业综合开发县管理工作,进一步规范开发县新增、恢复、暂停、取消、适时退出和行政区划变更确认等事项的管理,国家农业综合开发办公室研究制定了《国家农业综合开发县管理暂行办法》,现随文印发给你们,请认真遵照执行。在执行中有何问题和意见,请及时向国家农业综合开发办公室反馈。

国家农业综合开发县管理暂行办法

第一章 总 则

  第一条 为规范和加强国家农业综合开发县(市、区、旗、县级国有农牧场,以下统称“开发县”)管理,根据财政部《关于改革和完善农业综合开发若干政策措施的意见》(财发[2003]93号)的有关规定,制定本办法。
  第二条 本办法所称开发县管理是指开发县的新增、恢复、暂停、取消、适时退出、行政区划变更确认等事项的管理。
  第三条 开发县管理遵循总量控制、适度进出、奖优罚劣、分级管理原则。
  (一)总量控制。以2003年国家农发办批复为准,核定各省(区、市,新疆生产建设兵团,黑龙江省农垦总局,以下简称“各省”)开发县总数。各省经核定的开发县总数在执行中不得超过。
  (二)适度进出。今后各省申请新增开发县,必须相应先退出等量开发县。因严重违规违纪问题被取消开发县的,开发县总量相应减少。在开发县总数内,适时退出1个开发县,可以相应新增1个,也可在暂停开发县中择优恢复1个;暂停1个,可在暂停开发县中择优恢复1个;行政区划变更后只确认1个开发县。
  (三)奖优罚劣。工作绩效突出的开发县要受到奖励。项目和资金管理工作滞后或存在严重违规违纪问题的,要受到暂停或取消开发县的处罚。
  (四)分级管理。国家农发办审定开发县的新增、取消、适时退出、部分因违规违纪问题暂停开发县及相应恢复、行政区划变更确认等。省级农发办事机构审定部分暂停开发县及相应恢复。

第二章 新增开发县

  第四条 新增开发县是指符合农业综合开发立项条件的非农业综合开发县,按规定程序申报,由国家农发办审定为农业综合开发县。
  第五条 原有开发县适时退出后,允许其他开发潜力较大的农业大县(包括被取消的开发县2年内对存在问题整改到位后,重新申请立项)等量申请新增。
  第六条 新增开发县申报条件。
  (一)农业自然资源丰富,农业灌溉水源有保证,农田防洪有保障,水利灌排骨干工程基本具备;耕地资源比较充足,平原地区的耕地面积在20万亩以上,丘陵地区的耕地面积在10万亩以上,待开发治理的耕地相对集中连片;种植业、养殖业资源优势明显,具备一定产业基础;开发后有利于提高农业综合效益,增加农民收入。
  (二)县级政府和有关部门重视农业综合开发工作,农发办事机构人员配备适应工作的需要;地方财政配套资金有保障(政策规定不承担配套任务的县除外,下同);农民群众自愿搞开发的积极性高,农民筹资投劳有保证。
  (三)被取消的开发县申请重新立项必须对存在问题整改到位。
  第七条 新增开发县的申报和审定程序。
  (一)县级人民政府逐级向地级、省级农发办事机构提出农业综合开发立项申请(包括重新立项,下同),立项申请附带:本地农业综合开发五年规划,第一年度项目可行性研究报告,县级财政部门对本级配套资金的承诺意见,县级水利部门对本地水资源条件的鉴定意见,被取消的开发县对存在问题的整改情况等。
  (二)地级、省级农发办事机构负责对县级立项申请进行审核。经审核合格后,由省级农发办事机构向国家农发办报送立项申请(附报县级和地级农发办事机构出具的相关材料)。
  (三)国家农发办负责对省级农发办事机构报送的立项申请进行审核和实地考察评估(也可授权省级农发办事机构进行实地考察评估)。经评审合格并报部领导审定同意后,国家农发办正式向省级农发办事机构下达新增开发县通知。
  第八条 新增开发县的试行期为1年。1年试行期满后,国家农发办组织或授权省级农发办事机构对新增开发县的开发机构设置、人员配备、工作绩效等情况进行考核。经考核合格的,正式成为农业综合开发县;经考核不合格的,取消开发县。

第三章 恢复开发县

  第九条 恢复开发县是指在各省开发县总数内的开发县因工作滞后或违规违纪问题被暂停1年,1年后对存在问题整改到位,申请恢复开发县。
  第十条 凡有下列情形之一的,可申请恢复开发县。
  (一)因工作滞后,被省级农发办事机构实行末位暂停的开发县。
  (二)因项目和资金管理存在违规违纪问题受到暂停开发县处罚,1年内对存在问题整改到位后的开发县。
  第十一条 恢复开发县的申报和审定程序。
  (一)末位暂停的开发县,对存在问题整改到位后,由省级农发办事机构负责其恢复工作,恢复开发县情况报国家农发办备案。国家农发办自收文之日起1个月内不提出异议,即视为同意。
  (二)因违规违纪被暂停的开发县,对存在问题整改到位后,由县级农发办事机构(或县级人民政府)逐级向地级、省级农发办事机构报送恢复申请。其中:由省级农发办暂停的,由省级农发办审定恢复,报国家农发办备案;由国家农发办暂停的,需报国家农发办审定恢复。

第四章 暂停开发县

  第十二条 暂停开发县是指因工作滞后或存在违规违纪问题,由省级农发办事机构或国家农发办按程序暂停项目立项1年的开发县。暂停整改期限超过1年的,按取消项目县管理。
  第十三条 凡有下列情形之一的,应暂停开发县。
  (一)因工作滞后受到末位暂停处罚。以省为单位,每年暂停开发县比例不超过开发县总量的10%。具体标准由各省级农发办事机构负责制定,并报国家农发办备案。
  (二)因违规违纪问题受到暂停处罚。凡有下列情形之一的,应暂停项目县。
  1、由于申报失实、选项不准、实施不力等原因,致使项目建设失败甚至无法实施,造成项目财政资金损失。
  2、超越权限擅自调整已批复的项目实施计划,包括变更项目性质、建设地点、实施单位和调整项目建设内容,未按要求逐级报经省级农发办事机构或国家农发办批准,以及先调整后报批,情节严重的。
  3、以开发县为单位,挤占挪用项目财政资金累计在10万元以上(含)、100万元(含)以下。
  4、国家农发办组织竣工项目验收时,被评为“不合格”的开发县。
  5、对国家农发办检查、验收、人民来信核查,审计和财政监督部门检查中发现的问题,未按要求及时整改到位。
  6、违反《国家农业综合开发农民筹资投劳管理暂行规定》(国农办[2003]162号),项目申报前未按规定程序征求项目区农民意愿。
  第十四条 暂停开发县的整改期限为1年。1年内整改措施不到位的,取消开发县。1年内对存在问题整改完毕后,可逐级申请恢复开发县。
  第十五条 暂停开发县的审定程序。
  (一)国家农发办、省级农发办事机构负责对因违规违纪问题被暂停开发县的审定。国家农发办认定确需暂停某开发县,可直接向省级农发办事机构下达暂停该开发县的通知。
  (二)省级农发办事机构负责末位暂停开发县的审定,其审定结果报国家农发办备案。国家农发办自收文之日起1月内不提出异议,即视为同意。

第五章 取消开发县

第十六条 取消开发县是指对因项目和资金管理存在严重违规违纪问题、造成重大损失或恶劣影响的开发县,由国家农发办按程序取消其项目立项和资金安排的开发县。
第十七条 凡有下列情形之一的,应取消开发县。
(一)项目申报和实施中弄虚作假,如采用“以旧顶新”、“以虚冒实”等手段,套取上级财政资金;搞形象工程,欺骗上级部门和项目区农民群众。
(二)不执行农业综合开发财政无偿资金县级报帐制,不实行专账核算、专人管理和专款专用,违规用大额现金开支项目资金,财务管理混乱。
(三)以开发县为单位,挤占挪用项目财政资金累计达100万元以上。
(四)因项目和资金管理中存在的问题,在社会上造成重大恶劣影响,败坏农业综合开发声誉。
(五)强迫农民筹资投劳,并突破农业综合开发农民筹资投劳数额上限规定。
第十八条 被取消的开发县整改期限为2年,2年后对存在问题整改到位,措施得力的,允许按新增开发县程序逐级申请立项。
第十九条 取消开发县的审定程序。
(一)国家农发办负责对取消开发县的审定。国家农发办认定确需取消某开发县,可直接向省级农发办事机构下达取消该开发县的通知。
(二)省级农发办事机构认定确需取消某开发县,可以向国家农发办提出建议,并报送有关材料(附报开发县违规违纪问题的调查报告和相关证明材料)。如有疑问,国家农发办应组织进行实地核查。国家农发办确认后,正式向省级农发办事机构下达取消该开发县的通知。

第六章 适时退出

  第二十条 适时退出是指已无开发潜力或缺乏继续进行开发积极性的开发县,及时退出农业综合开发范围。
  第二十一条 凡有下列情形之一的开发县,应适时退出。
  (一)以开发县为单位,待改造中低产田面积,平原区低于1万亩,丘陵山区低于5000亩,不足安排1年土地治理任务的开发县应适时退出。
  (二)县级有关部门或农民群众缺乏继续进行开发积极性,或不愿执行农业综合开发政策制度的开发县,应适时退出。
  第二十二条 适时退出的申报审定程序。
  (一)国家农发办负责开发县适时退出的审定。
  (二)征求所在地级农发办事机构意见后,省级农发办事机构提出拟正常退出开发县名单,报送国家农发办审定。
  (三)缺乏继续进行开发积极性的开发县应以县级农发办事机构(或县人民政府)正式文件形式,向所在地级、省级农发办事机构提出申请,省级农发办事机构报送国家农发办审定。
  第二十三条 因无开发潜力适时退出的开发县,在退出开发范围后,仍允许申报国家农业综合开发产业化龙头项目。
  第二十四条 在不超过各省核定开发县总数的前提下,适时退出的开发县相应允许以新增或恢复开发县方式进行等量补充,新增和恢复开发县应按有关规定程序申报。

第七章 行政区划变更确认

  第二十五条 行政区划变更确认是指因国务院批准行政区划变更(包括撤消、合并和分离)后(以国务院正式文件为准),需要重新确认的开发县。行政区划变更确认由国家农发办负责审定。
  第二十六条 对行政区划变更后原有开发县一分为二或多个的,只确认其中一个开发任务最多或开发潜力最大的作为开发县。

第八章 附 则

  第二十七条 省级农发办事机构负责被暂停、取消、退出开发县和因行政区划变更未被确认的原开发县的后续管理工作,尤其要落实财政有偿资金的还款责任,确保财政有偿资金的按期、足额偿还,并要向当地干部和农民群众做好说明解释工作,确保各类在建项目工程的顺利完工。
  第二十八条 除部分暂停开发县及相应恢复外,省级以下(含省级)农发办事机构未经国家农发办批准不得擅自调整开发县。
  第二十九条 省级农发办事机构可根据本办法,结合本地区的实际情况,制定实施细则,并报国家农发办备案。
  第三十条 本办法由国家农发办负责解释。
  第三十一条 本办法自颁布之日起实行,原《国家农业综合开发办公室关于暂停或取消项目县资格的暂行规定》(国农办[2003]217号)同时废止。


下载地址: 点击此处下载

Provisions for Supervision of Drug Distribution

Commissioner of SFDA


Provisions for Supervision of Drug Distribution



(SFDA Decree No.26)

The Provisions for Supervision of Drug Distribution, adopted at the executive meeting of the State Food and Drug Administration on December 8, 2006, is hereby promulgated and shall go into effect as of May 1, 2007.


Shao Mingli
Commissioner of SFDA
January 31, 2007





Provisions for Supervision of Drug Distribution


Chapter I

Article 1 These Provisions are formulated for the purposes of strengthening drug supervision, regulating drug distribution order and ensuring drug quality in accordance with the Drug Administration Law of the People’s Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for Implementation of the Drug Administration Law of the People’s Republic of China (hereinafter referred to as Regulations for Implementation of the Drug Administration Law) and the requirements of the relevant law and regulations.

Article 2 Any institutions or individuals engaged in the purchase, sales and supervision of drugs in the People’s Republic of China shall abide by the Provisions.

Article 3 Drug manufacturers, distributors and medical institutions shall be responsible for the quality of the drugs that they produce, distribute or use.

Drug manufacturers and distributors shall carry out reforms and innovations in the direction of pharmaceutical logistics provided that drug quality is assured.

Article 4 The drug regulatory departments encourage individuals and organizations to involve in the social supervision on drug distribution. Individuals or organizations have the right to report or accuse of any violation of the Provisions to the drug regulatory departments.


Chapter II Supervision on Drug Purchase and Sales by Manufacturers and Distributors

Article 5 Drug manufacturers or distributors shall be responsible for their drug purchases and sales, and liable for the purchases and sales activities of their sales staff or offices in the name of their enterprise.

Article 6 Drug manufacturers or distributors shall train their purchase and sales staff on drug related laws, regulations and professional knowledge, and establish training records including time, venue, content and trainees.

Article 7 Drug manufacturers or distributors shall strengthen the management of the sales staff and set up specific rules for their sales behaviors.

Article 8 Drug manufacturers or distributors shall not store or spot trade drugs on the premises not approved by the drug regulatory departments.

Article 9 Drug manufacturers shall sell drugs that they produce in the name of themselves, and shall not sell any drug that they produce for contract manufacturing or any drugs produced by others.

Article 10 Where a drug manufacturer or wholesaler sells drugs, it shall provide the following materials:
(1) Copies of the Drug Manufacturing Certificate or Drug Supply Certificate, stamped with the seal of the enterprise, and the business license;
(2) Copies of the approval documents for the drug to be sold, stamped with the seal of the enterprise ;
(3) For import drug sales, relevant proof documents should be provided in accordance with the related provisions of the State.

Where a drug manufacturer or wholesaler sends any of its sales staff to sell drugs, it shall, in addition to the materials prescribed in the previous paragraph of this Article, provide a copy of the authorization letter with the seal of the enterprise. The original authorization letter shall contain the authorized drugs, regions and time of validity for drug sales, indicate the identity card numbers of the sales staff, and be stamped with the enterprise seal and legal representative seal (or signature). The sales staff shall show the original authorization letter and identity card for the check by drug purchasers.

Article 11 Where a drug manufacturer or wholesaler sells drugs, it shall provide sales document indicating supplier’s name, drug name, manufacturer, batch number, quantity, price, etc.

Where a drug retailer sells drugs, it shall provide sales document indicating drug name, manufacturer, quantity, price, batch number, etc.

Article 12 Where a drug manufacturer or distributor purchases drugs, it shall request, examine and retain the relevant certificates and documents of the supplier in accordance with the requirements set forth in Article 10 of the Provisions, and request and retain sales document in accordance with the requirements set forth in Article 11 of the Provisions.

The documents retained by the drug manufacturer or distributor in accordance with the previous paragraph of this Article shall be kept till one year after the date of expiry, but not less than three years.

Article 13 Where a drug manufacturer or distributor knows or should know that any person without certificates produces or distributes drugs, it shall not provide the person with any drug.

Article 14 A drug manufacturer or distributor shall not provide premises, qualifications documents, notes, etc. as conveniences for others to distribute drugs in its own name.

Article 15 A drug manufacturer or distributor shall not spot trade drugs by means of exhibition, exposition, trade fair, commodity fair or product promotion event.

Article 16 A drug distributor shall not purchase or sell pharmaceutical preparations prepared by medical institutions.

Article 17 A drug distributor shall not change its distribution mode without approval of the drug regulatory department.

A drug distributor shall operate within the approved distribution scope in the Drug Supply Certificate.

Article 18 A drug retailer shall, pursuant to the requirements of drug classification regulations set forth by the State Food and Drug Administration, sell prescription drugs in the presence of prescriptions.

Any drug retailer selling prescription drugs or Class A non-prescription drugs shall, in the absence of its licensed pharmacists and other qualified pharmaceutical professionals, put up a public notice and stop selling prescription drugs and Class A non-prescription drugs.

Article 19 For drugs that need low-temperature or cold storage as specified in drug insert sheets, the drug manufacturer or distributor shall transport and store the drugs with low-temperature or cold storage facilities in accordance with the relevant provisions.

When finding any drug manufacturer or distributor violates the requirements in the previous paragraph of this article, the drug regulatory department shall seal up or seize the drugs concerned immediately and deal with the matter in accordance with law.

Article 20 A drug manufacturer or distributor shall not provide the public with prescription drug or Class A non-prescription drug by means of tie-in sale, offering free drugs in association with sales of drug or commodity sale, etc.

Article 21 A drug manufacturer or distributor shall not sell prescription drugs directly to the public by post or over internet.

Article 22 Any illegal purchase of drugs is prohibited.


Chapter III Supervision on Drug Purchase and Storage by Medical Institutions

Article 23 The pharmacy established by a medical institution shall have the premise, equipment, storage facilities, hygienic environment, and pharmaceutical professionals required for drug dispensing. It shall also have the drug quality control units or personnel, and establish a system for drug storage.

Article 24 Where a medical insititution purchases drugs, it shall request, examine and retain the relevant certificates, documents and notes of the supplier in accordance with the requirements set forth in Article 12 of the Provisions.

Article 25 Where a medical institution purchases drugs, it shall establish and apply an examination and acceptance system, and keep authentic and complete purchase records. Purchase records shall indicate the adopted name of the drug in China, manufacturer (for Chinese crude drug, the origin should be noted), dosage form, date of expiry, drug approval number, supplier, quantity, price and date of purchase.

Drug purchase records shall be kept till one year after the date of expiry, but not less than three years.

Article 26 A medical institution shall establish and apply a system for drug storage and maintenance, and take necessary measures to ensure drug quality, such as cold storage, protection against freeze and humidity, ventilation, moisture proof, protection from direct light and fire, and avoidance of insects and rodents.

A medical institution shall store drugs and non-drug products separately; Chinese crude drugs, prepared slices of Chinese crude drugs, pharmaceuticals, and traditional Chinese medicine preparations shall be stored separately by category.

Article 27 A medical institution or family planning technical service institution shall not directly provide drugs for patients without diagnosis or treatment.

Article 28 A medical institution shall not sell prescription drugs directly to the public by post or over internet.

Article 29 Where a medical institution purchases drugs via a centralized tendering, it shall comply with the relevant requirements of the Drug Administration Law, Regulations for Implementation of the Drug Administration Law and the Provisions.


Chapter IV Legal Liabilities

Article 30 In any of the following circumstances, the drug manufacturer or distributor shall be instructed to rectify within a time limit and given a disciplinary warning; and if the drug manufacturer or distributor fails to do so, it shall be fined not less than RMB 5,000 yuan but not more than RMB 20,000 yuan:
(1) any drug manufacturer or distributor in violation of Article 6 of the Provisions;
(2) any drug manufacturer or wholesaler in violation of the first paragraph of Article 11 of the Provisions;
(3) any drug manufacturer or distributor, in violation of Article 12 of the Provisions, failing to keep the relevant documents as required.

Article 31 Any drug manufacturer or distributor in violation of Article 7 of the Provisions shall be given a disciplinary warning and instructed to rectify within a time limit.

Article 32 In accordance with the provisions in Article 73 of the Drug Administration Law, in any of the following circumstances, the drugs illegally sold and the illegal gains therefrom shall be confiscated, and the drug manufacturer or distributor shall be fined not less than two times but not more than five times the value of the drugs illegally sold:
(1) any drug manufacturer or distributor, in violation of Article 8 of the Provisions, spot trading drugs on the premises not approved by the drug regulatory departments.
(2) any drug manufacturer in violation of Article 9 of the Provisions;
(3) any drug manufacturer or distributor in violation of Article 15 of the Provisions;
(4) any drug distributor in violation of Article 17 of the Provisions.

Article 33 Any drug manufacturer or distributor, in violation of Article 8 of the Provisions, storing drugs on the premises not approved by the drug regulatory departments,shall be punished pursuant to the provisions in Article 74 of the Regulations for Implementation of the Drug Administration Law.

Article 34 Any drug retailer in violation of the provisions in the second paragraph of Article 11 of the Provisions shall be instructed to rectify and given a disciplinary warning; and if the drug retailer fails to do so within a time limit, it shall be fined not more than RMB 500 yuan.

Article 35 Where a drug manufacturer or distributor, in violation of Article 13 of the Provisions, knows or should know that any person without certificates produces or distributes drugs, but still provide the person with drugs, they shall be given a disciplinary warning, instructed to rectify and fined not more than RMB 10,000 yuan. If the circumstances are serious, they shall be fined not less than RMB 10,000 yuan but not more than RMB 30,000 yuan.

Article 36 Drug manufacturers and distributors in violation of Article 14 of the Provisions shall be punished pursuant to the provisions in Article 82 of the Drug Administration Law.

Article 37 Where a drug distributor, in violation of Article 16 of the Provisions, purchases or sells pharmaceutical preparations dispensed by medical institutions, it shall be punished pursuant to the provisions in Article 80 of the Drug Administration Law.

Article 38 Any drug retailer in violation of the first paragraph of Article 18 of the Provisions shall be instructed to rectify within a time limit and given a disciplinary warning; if it fails to do so or the circumstances are serious, it shall be fined not more than RMB 1,000 yuan.

Where a drug retailer, in violation of the second paragraph of Article 18 of the Provisions, sells prescription drugs or Class A non-prescription drugs in absence of licensed pharmacists or other qualified pharmaceutical professionals, it shall be instructed to rectify within a time limit and given a disciplinary warning; if it fails to do so, it shall be fined not more than RMB 1,000 yuan.

Article 39 Where a drug manufacturer or wholesaler, in violation of Article 19 of the Provisions, fails to transport drugs under low-temperature or cold storage conditions as specified in insert sheets, it shall be given a disciplinary warning and instructed to rectify within a time limit; if it fails to do as instructed, it shall be fined not less than RMB 5,000 yuan but not more than RMB 20,000 yuan. Where the drugs concerned are legally proved to be counterfeit or substandard drugs, the drug manufacturer or wholesaler shall be punished in accordance with the relevant provisions of the Drug Administration Law.

Where a drug manufacturer or wholesaler, in violation of Article 19 of the Provisions, fails to store drugs under low-temperature or cold storage conditions as specified in insert sheets, it shall be punished pursuant to the provisions in Article 79 of the Drug Administration Law. Where the drugs concerned are legally proved to be counterfeit or substandard drugs, the drug manufacturer or wholesaler shall be punished in accordance with the relevant provisions of the Drug Administration Law.

Article 40 Any drug manufacturer or distributor in violation of Article 20 of the Provisions shall be instructed to rectify within a time limit and given a disciplinary warning; if the drug manufacturer or distributor fails to do so or the circumstances are serious, they shall be fined not more than two times the value of the free drugs offered, but not more than RMB 30,000 yuan.

Article 41 Any institution, in violation of Article 23 to Article 27 of the Provisions, shall be instructed to rectify within a time limit; if the circumstances are serious, it shall be announced.

Article 42 Where a drug manufacturer or distributor in violation of Article 21 of the Provisions or a medical institution in violation of Article 28 of the Provisions sells prescription drugs directly to the public by post, over internet, etc., they shall be instructed to rectify, given a disciplinary warning, and fined not more than two times the value of the drugs sold, but not more than RMB 30,000 yuan.

Article 43 Any illegal purchase of drugs, in violation of Article 22 of the Provisions, shall be punished pursuant to the provisions in Article 73 of the Drug Administration Law.

Article 44 Where a drug regulatory department or its staff that neglects its duty fails to stop or punish illegal activities that should be stopped or punished, administrative sanctions shall be imposed to the person directly in charge and other persons directly responsible. If a crime is constituted, criminal liabilities shall be investigated in accordance with law.


Chapter V Supplementary Provisions

Article 45 Spot trading of drugs in the Provisions refers to the activity that drug manufacturers, distributors or their appointed sales staff carry and sell drugs to unspecified objects on spot other than the premises approved by the drug regulatory departments.

Article 46 With respect to the supervision on the distribution of specially controlled drugs, vaccines, and military medicines, if otherwise provided by the relevant laws, regulations and provisions, they shall prevail.

Article 47 The Provisions shall come into force as of May 1, 2007. As of the date when the Provisions goes into effect, the Provisions for Supervision of Drug Distribution (Interim) (SFDA Decree No.7) implemented on August 1, 1999 shall be annulled therefrom.




南通市授予外国人、港澳台同胞和海外侨胞荣誉证书、纪念证书规定

江苏省南通市人民政府


市政府关于印发《南通市授予外国人、港澳台同胞和海外侨胞荣誉证书、纪念证书规定》的通知


通政发〔2002〕187号 2002年9月27日



各县(市)、区人民政府,市各委、办、局,市各直属单位:
  《南通市授予外国人、港澳台同胞和海外侨胞荣誉证书、纪念证书规定》已经2002年9月18日市十一届政府第53次常务会议讨论通过,现予公布,自2002年10月1日起施行。

南通市授予外国人、港澳台同胞和海外侨胞荣誉证书、纪念证书规定

第一条 为褒扬和嘉奖对我市经济建设、社会事业、对外交流与合作等方面做出重要贡献的外国人、港澳台同胞和海外侨胞,促进我市经济建设和社会进步,制定本规定。

第二条 本规定所称荣誉证书、纪念证书,是指南通市人民政府为褒扬和嘉奖对南通经济社会发展作出积极贡献的外国人、港澳台同胞、海外侨胞,根据其所作的贡献而颁发的写实性荣誉性证书。

第三条 荣誉证书、纪念证书以南通市市长的名义授予。荣誉证书、纪念证书由南通市人民政府统一制定规范格式。

第四条 南通市外事办公室负责全市授予外国人、港澳同胞荣誉证书、纪念证书申报受理的协调和管理。

南通市政府侨务办公室负责全市授予海外侨胞荣誉证书、纪念证书申报受理的协调和管理。

南通市政府台湾事务办公室负责全市授予台湾同胞荣誉证书、纪念证书申报受理的协调和管理。

第五条 对具备下列条件之一者可授予荣誉证书:

(一)对本市经济建设和社会事业发展提出重要合理化建议被采纳并取得显著成效的;
(二)为本市提供国际合作信息,介绍、推进重大利用外资项目或多个外资项目落户本市,以及为本市拓展国际市场、扩大进出口业务,发展开放型经济作出较大贡献的;
(三)为本市采用高新技术和先进适用技术,发展信息工程、生物医药、新材料等高新技术提供信息、咨询或帮助并取得较大成效的;
(四)为本市无偿引进先进技术、设备提供帮助,或捐赠、赞助款物折合人民币累计达100万元以上的;
(五)与本市友好交流合作5年以上,或所经营管理企业成为本市纳税大户及被评为市级先进,或其个人工作表现等方面优秀的;
(六)有其他特殊贡献应予表彰的。

第六条 对具备下列条件之一者可授予纪念证书:

(一)介绍、推进较大利用外资项目或引进外资项目落户本市的;
(二)工作认真负责,圆满完成工作任务,热情向本市传授先进技术或管理经验的
(三)热情宣传推介南通,有利于本市对外交往和开展国际合作的;
(四)在南通工作并与本市友好合作满2年以上的。

第七条 申请授予荣誉证书、纪念证书的,由外国人、港澳台同胞、海外侨胞在本市工作的单位或其接待单位,根据其业绩和友好态度写出推荐材料,经县(市)、区人民政府或市主管部门初审后,送市外事办公室或市政府台湾事务办公室或市政府侨务办公室审核,报市人民政府审定。

第八条 授予外国人、港澳台同胞、海外侨胞荣誉证书、纪念证书的仪式由南通市人民政府举行,由市长或受市长委托的副市长、秘书长颁发。

第九条 外国人、港澳台同胞、海外侨胞接受荣誉证书、纪念证书,应由本人参加颁发仪式。

第十条 对获得荣誉证书、纪念证书的外国人、港澳台同胞、海外侨胞的事迹,可通过适当形式予以宣传报道,并应事先征得当事人同意。

第十一条 本规定自2002年10月1日起施行。